Another ECJ fudge as GSK parallel trade case rumbles on
This article was originally published in Scrip
Appeal, cross-appeal, response to the cross appeal, appeal, appeal, appeal – and this has only touched on the very the start of the Judgement handed down recently by the European Court of Justice (ECJ) in the GlaxoSmithKline Services v Commission parallel trade case. It is clear from the numerous forms of order sought in this case that it is both extremely important and fantastically confusing. Indeed, the ECJ’s initial approach was summed up at the beginning: “For the sake of clarity and given their similarity, certain of the grounds of appeal put forward by the appellants will be considered separately, whilst others will be examined together.” Did someone say “clarity”?
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.